‘Made in Canada’ Solution Will Transform Cancer Care For Canadians

There has been a significant decrease in cancer diagnosis and treatment, as health care systems adapt to the demands of the pandemic.

Nearly half of Canadians are expected to receive a diagnosis of cancer in their lifetime, and delaying the time between diagnosis and treatment increases risk of dying from cancer by 10%.

While the pandemic has posed challenges to cancer patients and their caregivers, a new precision oncology software, project CanDETECT, offers a solution to monitor cancer recovery and recurrence for millions of Canadian cancer survivors.

With co-investment from Canada’s Digital Technology Supercluster, CanDETECT is led by Imagia Canexia Health and brings together break-through research and development from Microsoft, Queen’s University, University Health Network, BC Cancer Research and DNAstack.

Vancouver’s Canexia Health merged with Montréal’s Imagia Cybernetics earlier this year.

Imagia Canexia Health’s AI-based oncology software will identify and predict the best available targeted therapies and/or clinical trials for cancer patients throughout the course of their treatment and will analyze and track how each patient responds to therapy over time.

“The AI-based oncology software being developed and tested as a part of the CanDETECT project will enable clinicians to perform a real-time assessment of tumor status, detect earlier signs of patient relapse and recommend alternative treatment options, ensuring the best possible outcome faster, more accurately and at less cost than current solutions,” said Geralyn Ochab, CEO of Imagia Canexia Health.

“This ‘Made in Canada’ solution will transform cancer care for Canadians.”